Revenue recognition and accounts receivable (Tables)

3 Months Ended

Mar. 31, 2021

Revenue Recognition And Accounts Receivable [Abstract]

Schedule of Net Sales by Major Product Category by Reporting Segment

The table below presents net sales by major product category by reporting segment:

	Three Months Ended March 31,
(U.S. Dollars, in thousands)	2021		2020		Change
Bone Growth Therapies	$	42,947	$	45,443		-5.5	%
Spinal Implants		25,701		22,926		12.1	%
Biologics		13,692		13,949		-1.8	%
Global Spine		82,340		82,318		0.0	%
Global Orthopedics		23,253		22,505		3.3	%
Net sales	$	105,593	$	104,823		0.7	%

Schedule of Components Net Sales

The table below presents product sales and marketing service fees, which are both components of net sales:

	Three Months Ended March 31,
(U.S. Dollars, in thousands)	2021		2020
Product sales	$	92,263	$	91,421
Marketing service fees		13,330		13,402
Net sales	$	105,593	$	104,823

Allowances for Expected Credit Losses

The following table provides a detail of changes in the Company’s allowance for expected credit losses for the three months ended March 31, 2021 and 2020:

(U.S. Dollars, in thousands)	Three Months Ended March 31, 2021			Three Months Ended March 31, 2020
Allowance for expected credit losses beginning balance	$	4,848		$	3,987
Impact of adoption of ASU 2016-13		—			1,120
Current period provision (recovery) for expected credit losses		(182	)		679
Writeoffs charged against the allowance and other		(46	)		(114	)
Effect of changes in foreign exchange rates		(114	)		(81	)
Allowance for expected credit losses ending balance	$	4,506		$	5,591